I. Lecander

发表

Factors of the plasminogen activator system in human testis, as demonstrated by in-situ hybridization and immunohistochemistry.

P. Abrahamsson, M. Gunnarsson, I. Lecander, 1999, Molecular human reproduction.

Fluid Characteristics of Benign Ovarian Cysts: Correlation With Recurrence After Puncture

B. Casslén, E. Andolf, C. Jörgensen, 1995, Obstetrics and gynecology.

Purification of a Specific Placental Plasminogen Activator Inhibitor by Monoclonal Antibody and Its Complex Formation with Plasminogen Activator

A. Lundblad, T. Brodin, B. Åstedt, 1985, Thrombosis and Haemostasis.

Cellular Localisation in Placenta of Placental Type Plasminogen Activator Inhibitor

I. Hägerstrand, B. Åstedt, I. Lecander, 1986, Thrombosis and Haemostasis.

Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women.

A. Bergqvist, K. Carlström, B. Åstedt, 1998, Fertility and sterility.

Plasminogen activator inhibitor 2 in menstrual endometrium and in primary cultures of endometrial cells

B. Casslén, J. Nordengren, I. Lecander, 1996 .

Differential expression of uPA in an aggressive (DU 145) and a nonaggressive (1013L) human prostate cancer xenograft

U. Stenram, B. Dahllöf, F. Dagnaes-hansen, 1995, The Prostate.

Passage of the menopause is followed by haemostatic changes.

C. Lindoff, B. Åstedt, G. Martinsson, 1993, Maturitas.

An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.

L. Holmberg, B. Åstedt, I. Lecander, 1978, Biochimica et biophysica acta.

Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.

C. Lindoff, B. Åstedt, G. Martinsson, 1996, Maturitas.

Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma

B. Åstedt, I. Lecander, 1986, British journal of haematology.

Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.

B. Åstedt, I. Lecander, B. Bladh, 1985, Scandinavian journal of clinical and laboratory investigation.

The placental type plasminogen activator inhibitor, PAI 2

T. Ny, B. Åstedt, I. Lecander, 1987 .

Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies.

K. Danø, P. Andreasen, A. Henschen, 1987, Thrombosis research.

The urokinase inhibitor p‐aminobenzamidine inhibits growth of a human prostate tumor in scid mice

B. Åstedt, I. Lecander, S. Batra, 1995, International journal of cancer.

PLASMINOGEN ACTIVATOR INHIBITOR OF PLACENTAL TYPE IN PREECLAMPSIA

J. Borm, K. Boer, I. Lecander, 1987 .

Fibrinolysis during normal human pregnancy: complex inter‐relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time

M. Greaves, F. Preston, B. Åstedt, 1988, British journal of haematology.

Production of plasminogen activator inhibitor type-2 in human peripheral blood monocytes upregulated in vitro by the quinoline-3-carboxamide, Linomide

B. Åstedt, I. Lecander, B. Kinnby, 1996 .

Binding of urokinase to plasma proteinase inhibitors.

L. Holmberg, B. Åstedt, I. Lecander, 1980, Scandinavian journal of clinical and laboratory investigation.

Fibrinolysis in the Peritoneal Fluid During Adhesions, Endometriosis and Ongoing Pelvic Inflammatory Disease

G. Edelstam, B. Åstedt, I. Lecander, 1998, Inflammation.

Peaks in plasma plasminogen activator inhibitor‐1 concentration may explain thrombotic events in cases of pancreatic carcinoma

A. Andrén-sandberg, B. Åstedt, I. Lecander, 1992, Cancer.

The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis.

L. Matsson, I. Lecander, B. Kinnby, 1994, Scandinavian journal of dental research.

Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid

B. Åstedt, G. Martinsson, I. Lecander, 1991 .

Specific plasminogen activator inhibitor of placental type PAI 2 occurring in amniotic fluid and cord blood.

B. Åstedt, I. Lecander, 1987, The Journal of laboratory and clinical medicine.

Occurrence of a specific plasminogen activator inhibitor of placental type, PAI-2, in men and non-pregnant women

B. Åstedt, I. Lecander, 1989 .

Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures.

J. Thorell, L. Holmberg, B. Åstedt, 1981, European journal of cancer.

Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor

R. Roblin, B. Åstedt, I. Lecander, 1984, British journal of haematology.

Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.

S. Thorsen, I Lecander, B Astedt, 1988, European journal of biochemistry.

Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.

L. Holmberg, A. Kristoffersson, B. Åstedt, 1982, Scandinavian journal of clinical and laboratory investigation.

Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation.

N. Lang, L. Matsson, P. Lindberg, 2001, Archives of oral biology.

Description of the plasminogen activating system in canine gingival crevicular fluid

L. Matsson, P. Lindberg, I. Lecander, 2000 .

Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization.

L. Matsson, P. Lindberg, I. Lecander, 1999, Archives of oral biology.

Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival fluid from 8-9-year-old children.

L. Granath, I. Lecander, B. Kinnby, 1993, Scandinavian journal of dental research.

Urokinase binds to a plasminogen activator inhibitor type-2-like molecule in placental microvillous membranes.

L. Lund, P. Andreasen, J. Gliemann, 1989, Biochimica et biophysica acta.

Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies.

S. Hansson, C. Lindoff, A. Jonasson, 1999, Human fertility.

Activator Inhibitors in Blood and Tumour Fluids of Patients with Ovarian Cancer

I. Lecander, T. Bossmar, B. Casslh, 1994 .

Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.

B. Casslén, B Casslén, T Bossmar, 1994, European journal of cancer.

Significance of the Plasminogen Activator Inhibitor of Placental Type (PAI-2) In Pregnancy

C. Lindoff, B. Åstedt, I. Lecander, 1998, Seminars in thrombosis and hemostasis.

The effect of cervical dilatation by laminaria tent in first trimester legal abortions on blood loss related to fibrinolytic activity in the decidua and placenta

A. Jonasson, B. Åstedt, I. Lecander, 1989, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Plasminogen activators in the human endometrium, cellular origin and hormonal regulation

T. Ny, I. Lecander, S. Urano, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Placental and decidual u-PA, t-PA, PAI-1 and PAI-2 concentrations, as affected by cervical dilatation with laminaria tents or Hegar dilators.

A. Jonasson, B. Åstedt, I. Lecander, 1989, Thrombosis research.

Urokinase-producing Tumour Growth in SCID Mice Inhibited by Recombinant PAI-2

B. Åstedt, I. Lecander, A. Billström, 1995 .

Placental-type plasminogen activator inhibitor in preeclampsia.

J. Borm, I. Lecander, P. Treffers, 1988, American journal of obstetrics and gynecology.

Depression of plasminogen activator activity during pregnancy by the placental inhibitor PAI 2

I. Nilsson, B. Åstedt, I. Lecander, 1988 .

Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women

I. Nilsson, B. Åstedt, I. Lecander, 1986, British journal of haematology.

High tissue content of urokinase plasminogen activator (u‐PA) is associated with high stromal expression of u‐PA mRNA in poorly differentiated serous ovarian carcinoma

C. Borgfeldt, B. Casslén, B. Åstedt, 1998, International journal of cancer.

PLASMINOGEN ACTIVATOR INHIBITORS OF TYPE 1 (PAI-1) AND TYPE 2 (PAI-2) ARE PRESENT IN ASCITIC FLUID FROM PATIENTS WITH OVARIAN CARCINOMA

K. Danø, P. Andreasen, L. Nielsen, 1987, Thrombosis and Haemostasis.

Plasminogen activator inhibitor type 1 and 2 in human breast cancer.

M. Duffy, M. Duch, P. Andreasen, 1992, Biochemical Society transactions.

Fibrinolytic components in individual consecutive plasma samples during normal pregnancy

C. Lindoff, B. Åstedt, I. Lecander, 1993 .

Identity between the placental protein PP10 and the specific plasminogen activator inhibitor of placental type PAI-2.

K. Radtke, A. Henschen, H. Bohn, 1991, Biochimica et biophysica acta.

Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumour vessel blood from patients with ovarian carcinoma

B. Casslén, P. Andreasen, B. Åstedt, 1990 .

Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.

P. Geborek, T. Saxne, I. Lecander, 1993, The Journal of rheumatology.

Rebound increase of PAI‐1 following local intra‐arterial rt‐PA infusion, a possible cause of reocclusion

L. Norgren, B. Åstedt, I. Lecander, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.